1. Carlsmed launched aprevo® Technology for cervical fusion surgeries. 2. Early clinical data shows improved alignment and patient-specific implants. 3. Over 370,000 cervical fusion surgeries were performed in the U.S. this year. 4. Strong demand and positive feedback suggest redefining cervical spine surgery standards. 5. Presentations at CSRS meeting highlight clinical experiences and technological benefits.
FAQ
Why Bullish?
The successful launch of aprevo® could drive significant revenue growth, similar to the initial reception of their lumbar platform.
How important is it?
The advancements in Carlsmed's technology address a growing market need, likely affecting stock performance positively.
Why Short Term?
Initial clinical data and presentations could quickly influence market perception and investor confidence.
Carlsmed Launches aprevo® Technology Platform for Cervical Fusion Surgeries
CARLSBAD, Calif., Dec. 3, 2025 – Carlsmed, Inc. (Nasdaq: CARL) has officially announced the U.S. commercial launch of its aprevo® Technology Platform, designed specifically for cervical fusion surgeries. This innovative platform will be showcased at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting taking place in Washington, D.C., from December 3-6, 2025.
Details of the aprevo® Cervical Interbody System
The aprevo® Cervical Interbody System is an extension of Carlsmed’s personalized spine platform, integrating AI-driven preoperative planning with 3D-printed, patient-specific implants tailored to each individual's anatomy and pathology. This cervical system builds upon the successful foundation established by the aprevo® lumbar platform, which has reported lower complication rates and fewer revision surgeries compared to conventional stock implants.
With over 370,000 cervical fusion surgeries performed in the U.S. this year, the demand for advanced technologies that enhance alignment and anatomical fit in patients with compromised bone quality continues to rise. The early clinical experience with the aprevo® system indicates:
- Efficient integration into surgical workflows.
- Precise implant fit with maximized endplate coverage.
- Enhanced ability to achieve planned sagittal and coronal alignment goals compared to standard stock implants.
Quotes from Leadership
Mike Cordonnier, Chairman and CEO of Carlsmed, expressed enthusiasm about this launch: “We are excited to bring the aprevo® platform to cervical fusion procedures, representing an important milestone in our mission to transform spine surgery. With positive clinical feedback from our first 50+ cases, strong reimbursement support, and accelerating demand, we believe our cervical system has the potential to redefine the standard of care in cervical spine surgery.”
Dr. Andrew Chan, MD, from Columbia University / New York-Presbyterian Och Spine Hospital, emphasized the significance of personalization in this field: “With aprevo® Cervical, we’re able to preoperatively plan in three dimensions and deliver a device that’s matched to each patient’s unique anatomy. That level of precision enhances how we correct alignment while helping broaden access to anterior cervical procedures for more complex patients.”
CSRS Lunch Workshop Details
As part of the CSRS Annual Meeting, Carlsmed will present early clinical data during a valuable workshop:
- Date: Thursday, December 4, 2025
- Time: 12:30-1:30 PM EST
- Location: Meeting Room 8 - Meeting Level
- Panel Presenters:
- Andrew Chan, MD, Columbia University
- Deb Bhowmick, MD, Duke University
- Venu Nemani, MD, PhD, Virginia Mason Medical Center
About Carlsmed
Carlsmed, Inc. is at the forefront of medical technology, pioneering AI-enabled personalized spine surgery solutions. The company's mission focuses on improving surgical outcomes while reducing healthcare costs in the field of spine surgery and beyond.
Forward-Looking Statements
This announcement contains forward-looking statements regarding future expectations and prospects. Such statements involve risks and uncertainties, including demand for the Company's products and the potential market size for its innovative technology platform. For detailed risk factors, please refer to Carlsmed’s Registration Statement on Form S-1 filed with the U.S. Securities and Exchange Commission.